- Home
- APLM vs KTTA Comparison
APLM vs KTTA Comparison
Compare APLM & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- KTTA
- Stock Information
- Founded
- APLM 2016
- KTTA 2020
- Country
- APLM United States
- KTTA United States
- Employees
- APLM N/A
- KTTA N/A
- Industry
- APLM Blank Checks
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- KTTA Health Care
- Exchange
- APLM Nasdaq
- KTTA Nasdaq
- Market Cap
- APLM 6.1M
- KTTA 5.5M
- IPO Year
- APLM N/A
- KTTA 2021
- Fundamental
- Price
- APLM $18.43
- KTTA $0.72
- Analyst Decision
- APLM
- KTTA
- Analyst Count
- APLM 0
- KTTA 0
- Target Price
- APLM N/A
- KTTA N/A
- AVG Volume (30 Days)
- APLM 89.6K
- KTTA 203.1K
- Earning Date
- APLM 09-30-2025
- KTTA 11-12-2025
- Dividend Yield
- APLM N/A
- KTTA N/A
- EPS Growth
- APLM N/A
- KTTA N/A
- EPS
- APLM N/A
- KTTA N/A
- Revenue
- APLM $198,000.00
- KTTA N/A
- Revenue This Year
- APLM $415.15
- KTTA N/A
- Revenue Next Year
- APLM N/A
- KTTA N/A
- P/E Ratio
- APLM N/A
- KTTA N/A
- Revenue Growth
- APLM N/A
- KTTA N/A
- 52 Week Low
- APLM $3.66
- KTTA $0.65
- 52 Week High
- APLM $35.98
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- APLM 90.29
- KTTA 43.16
- Support Level
- APLM $3.66
- KTTA $0.74
- Resistance Level
- APLM $6.37
- KTTA $0.81
- Average True Range (ATR)
- APLM 1.65
- KTTA 0.06
- MACD
- APLM 1.20
- KTTA -0.01
- Stochastic Oscillator
- APLM 85.30
- KTTA 11.45
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).